# Study To Evaluate The Efficacy And Safety Of Balovaptan In Adults With Post-Traumatic Stress Disorder (PTSD)

> **NCT05401565** · PHASE2 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 29 (actual)

## Conditions studied

- Stress Disorders, Post-Traumatic

## Interventions

- **DRUG:** Balovaptan
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05401565
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-08-02
- **Primary completion:** 2023-10-05
- **Final completion:** 2023-10-05
- **Target enrollment:** 29 (ACTUAL)
- **Last updated:** 2024-04-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05401565

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05401565, "Study To Evaluate The Efficacy And Safety Of Balovaptan In Adults With Post-Traumatic Stress Disorder (PTSD)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT05401565. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*